EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dixon, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dixon, A.
Evidence-Based Medicine 2002; 7:158
© 2002 Evidence-Based Medicine


Therapeutics

Pharmacist review changed more repeat prescriptions for elderly patients than usual general practice review

Zermansky AG, Petty DR, Raynor DK, et al.Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice.BMJ 2001 Dec 8;323:1340–3[Abstract/Free Full Text]

QUESTION: In elderly patients who receive repeat prescriptions, is a clinical review of medications by a pharmacist more effective than usual general practice review for increasing medication changes and reducing costs?

Key Words: patient participation • pharmacists • physician’s practice patterns

The first 150 words of the full text of this article appear below.

Design
12 month randomised {allocation concealed*}{dagger}, {unblinded}{dagger},* controlled trial.

Setting
4 general practices in Leeds, UK.

Patients
1188 patients who were >=65 years of age (mean age 74 y, 56% women); were receiving >= 1 drug on repeat prescription as of 1 June 1999; and were from a general practice in which prescribing costs were average and that had >=4 partners, computerised repeat prescribing, and no previous or current clinical pharmacist involvement. Patients were excluded if they lived in nursing or residential homes, had a terminal illness, or were enrolled in clinical trials. Follow up was 95%.

Intervention
608 patients were allocated to pharmacist review, which had 3 components. In stage 1, the pharmacist evaluated the patients; their illnesses; and their medications, including adherence. In stage 2, the pharmacist evaluated the patients’ medication regimen in terms of need for ongoing drugs, side effects, inadequate treatment, and cost. In stage 3, if necessary, . . . [Full text of this article]

Anthony Dixon, MB, ChB

University of Hong Kong
Hong Kong, China







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 by the BMJ Publishing Group Ltd.